Cannabidiol Reduces Seizures Following CNS Infection with Theiler's Murine Encephalomyelitis Virus

Overview

Journal Epilepsia Open

Date 2019 Aug 24

PMID 31440724

Citations 13

Authors

Dipan C Patel

Glenna Wallis

Robert S Fujinami

Karen S Wilcox

Misty D Smith

Affiliations

Soon will be listed here.

Abstract

Objective: C57BL/6J mice infected with Theiler's murine encephalomyelitis virus (TMEV) develop acute behavioral seizures in the first week of infection and later develop chronic epilepsy. The TMEV model provides a useful platform to test novel antiseizure therapeutics. The present study was designed to test the efficacy of cannabidiol (CBD) in reducing acute seizures induced by viral infection.

Methods: C57BL/6J mice were infected intracortically with 2 × 10 plaque-forming units of TMEV. Mice were divided into two treatment groups-1) CBD-treated mice and 2) vehicle-treated mice. Frequency and severity of acute seizures were evaluated by video-monitoring the mice four times daily by the experimenter blinded to the treatment group.

Results: Cannabidiol (180 mg/kg; 360 mg/kg/day) decreased both the frequency and severity of acute behavioral seizures following TMEV infection, but 150 mg/kg of CBD did not improve overall seizure outcome. The time to peak effect (TPE) of CBD in the 6 Hz 32 mA psychomotor seizure test using C57BL/6J mice was observed at 2 hours post-CBD treatment. Interestingly, CBD (150 mg/kg) significantly reduced frequency and severity of TMEV-induced acute seizures at 2 hours post-CBD treatment. These results suggest that CBD could be effective in decreasing TMEV-induced acute seizures when the seizure test is conducted at the TPE of CBD.

Significance: Cannabinoids are increasingly studied for their potential antiseizure effects. Several preclinical and clinical studies provide evidence that CBD could be an effective therapy for intractable epilepsies. The present study corroborates those previous findings and provides an opportunity to investigate pharmacokinetics, pharmacodynamics, and mechanism(s) of antiseizure effects of CBD in the TMEV model, which may help to design future clinical studies more effectively.

Citing Articles

Enhancement of Glutamate Uptake as Novel Antiseizure Approach: Preclinical Proof of Concept.

Kaminski K, Socala K, Abram M, Jakubiec M, Reeb K, Temmermand R Ann Neurol. 2024; 97(2):344-357.

PMID: 39512205 PMC: 11740271. DOI: 10.1002/ana.27124.

Innovative drug discovery strategies in epilepsy: integrating next-generation syndrome-specific mouse models to address pharmacoresistance and epileptogenesis.

Barker-Haliski M, Hawkins N Expert Opin Drug Discov. 2024; 19(9):1099-1113.

PMID: 39075876 PMC: 11390315. DOI: 10.1080/17460441.2024.2384455.

Interplay between the Glymphatic System and the Endocannabinoid System: Implications for Brain Health and Disease.

Osuna-Ramos J, Camberos-Barraza J, Torres-Mondragon L, Rabago-Monzon A, Camacho-Zamora A, Valdez-Flores M Int J Mol Sci. 2023; 24(24).

PMID: 38139290 PMC: 10743431. DOI: 10.3390/ijms242417458.

Infection-induced epilepsy is caused by increased expression of chondroitin sulfate proteoglycans in hippocampus and amygdala.

Patel D, Swift N, Tewari B, Browning J, Prim C, Chaunsali L bioRxiv. 2023; .

PMID: 37292901 PMC: 10245664. DOI: 10.1101/2023.05.16.541066.

Advances and Challenges of Cannabidiol as an Anti-Seizure Strategy: Preclinical Evidence.

Zavala-Tecuapetla C, Luna-Munguia H, Lopez-Meraz M, Cuellar-Herrera M Int J Mol Sci. 2022; 23(24).

PMID: 36555823 PMC: 9783044. DOI: 10.3390/ijms232416181.

References

Kozela E, Lev N, Kaushansky N, Eilam R, Rimmerman N, Levy R . Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57BL/6 mice. Br J Pharmacol. 2011; 163(7):1507-19. PMC: 3165959. DOI: 10.1111/j.1476-5381.2011.01379.x. View

Hesdorffer D, Logroscino G, Cascino G, Annegers J, Hauser W . Risk of unprovoked seizure after acute symptomatic seizure: effect of status epilepticus. Ann Neurol. 1998; 44(6):908-12. DOI: 10.1002/ana.410440609. View

Vezzani A, French J, Bartfai T, Baram T . The role of inflammation in epilepsy. Nat Rev Neurol. 2010; 7(1):31-40. PMC: 3378051. DOI: 10.1038/nrneurol.2010.178. View

Cusick M, Libbey J, Patel D, Doty D, Fujinami R . Infiltrating macrophages are key to the development of seizures following virus infection. J Virol. 2012; 87(3):1849-60. PMC: 3554195. DOI: 10.1128/JVI.02747-12. View

Jones N, Glyn S, Akiyama S, Hill T, Hill A, Weston S . Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures. Seizure. 2012; 21(5):344-52. DOI: 10.1016/j.seizure.2012.03.001. View

Devinsky O, Patel A, Cross J, Villanueva V, Wirrell E, Privitera M . Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. N Engl J Med. 2018; 378(20):1888-1897. DOI: 10.1056/NEJMoa1714631. View

Wallace M, Wiley J, Martin B, DeLorenzo R . Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects. Eur J Pharmacol. 2002; 428(1):51-7. DOI: 10.1016/s0014-2999(01)01243-2. View

Libbey J, Kennett N, Wilcox K, White H, Fujinami R . Interleukin-6, produced by resident cells of the central nervous system and infiltrating cells, contributes to the development of seizures following viral infection. J Virol. 2011; 85(14):6913-22. PMC: 3126579. DOI: 10.1128/JVI.00458-11. View

Devinsky O, Cross J, Laux L, Marsh E, Miller I, Nabbout R . Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. N Engl J Med. 2017; 376(21):2011-2020. DOI: 10.1056/NEJMoa1611618. View

10.

Scheirer C, RAY W, Hare N . The analysis of ranked data derived from completely randomized factorial designs. Biometrics. 1976; 32(2):429-34. View

11.

Klein B, Jacobson C, Metcalf C, Smith M, Wilcox K, Hampson A . Evaluation of Cannabidiol in Animal Seizure Models by the Epilepsy Therapy Screening Program (ETSP). Neurochem Res. 2017; 42(7):1939-1948. DOI: 10.1007/s11064-017-2287-8. View

12.

Rosenberg E, Tsien R, Whalley B, Devinsky O . Cannabinoids and Epilepsy. Neurotherapeutics. 2015; 12(4):747-68. PMC: 4604191. DOI: 10.1007/s13311-015-0375-5. View

13.

Guilliams K, Rosen M, Buttram S, Zempel J, Pineda J, Miller B . Hypothermia for pediatric refractory status epilepticus. Epilepsia. 2013; 54(9):1586-94. PMC: 3975144. DOI: 10.1111/epi.12331. View

14.

Bhuyan P, Patel D, Wilcox K, Patel M . Oxidative stress in murine Theiler's virus-induced temporal lobe epilepsy. Exp Neurol. 2015; 271:329-34. PMC: 4848026. DOI: 10.1016/j.expneurol.2015.06.012. View

15.

Hegde V, Nagarkatti P, Nagarkatti M . Role of myeloid-derived suppressor cells in amelioration of experimental autoimmune hepatitis following activation of TRPV1 receptors by cannabidiol. PLoS One. 2011; 6(4):e18281. PMC: 3069975. DOI: 10.1371/journal.pone.0018281. View

16.

Patel D, Wallis G, Fujinami R, Wilcox K, Smith M . Cannabidiol reduces seizures following CNS infection with Theiler's murine encephalomyelitis virus. Epilepsia Open. 2019; 4(3):431-442. PMC: 6698680. DOI: 10.1002/epi4.12351. View

17.

Umpierre A, Remigio G, Dahle E, Bradford K, Alex A, Smith M . Impaired cognitive ability and anxiety-like behavior following acute seizures in the Theiler's virus model of temporal lobe epilepsy. Neurobiol Dis. 2014; 64:98-106. PMC: 4353639. DOI: 10.1016/j.nbd.2013.12.015. View

18.

OConnell B, Gloss D, Devinsky O . Cannabinoids in treatment-resistant epilepsy: A review. Epilepsy Behav. 2017; 70(Pt B):341-348. DOI: 10.1016/j.yebeh.2016.11.012. View

19.

Burstein S . Cannabidiol (CBD) and its analogs: a review of their effects on inflammation. Bioorg Med Chem. 2015; 23(7):1377-85. DOI: 10.1016/j.bmc.2015.01.059. View

20.

Mecha M, Feliu A, Inigo P, Mestre L, Carrillo-Salinas F, Guaza C . Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: a role for A2A receptors. Neurobiol Dis. 2013; 59:141-50. DOI: 10.1016/j.nbd.2013.06.016. View